These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 25926523)

  • 1. Four-month fluoroquinolone-containing regimens are inferior to standard 6-month tuberculosis treatment.
    Sterling TR
    Evid Based Med; 2015 Aug; 20(4):128-9. PubMed ID: 25926523
    [No Abstract]   [Full Text] [Related]  

  • 2. Shorter moxifloxacin-based regimens for drug-sensitive tuberculosis.
    Alffenaar JW; Gumbo T; Aarnoutse R
    N Engl J Med; 2015 Feb; 372(6):576. PubMed ID: 25651257
    [No Abstract]   [Full Text] [Related]  

  • 3. Shorter moxifloxacin-based regimens for drug-sensitive tuberculosis.
    Sellier PO; Clevenbergh P; Bergmann JF
    N Engl J Med; 2015 Feb; 372(6):577. PubMed ID: 25651258
    [No Abstract]   [Full Text] [Related]  

  • 4. Shorter moxifloxacin-based regimens for drug-sensitive tuberculosis.
    Gillespie SH; Mendel CM;
    N Engl J Med; 2015 Feb; 372(6):577. PubMed ID: 25651256
    [No Abstract]   [Full Text] [Related]  

  • 5. Shortening treatment for tuberculosis--to basics.
    Warner DF; Mizrahi V
    N Engl J Med; 2014 Oct; 371(17):1642-3. PubMed ID: 25337754
    [No Abstract]   [Full Text] [Related]  

  • 6. [Floracide, a Russian 3rd generation fluoroquinolone in complex therapy of tuberculosis].
    Sokolova GB; Kirtaeva OV; Lazareva IaV; Tsybanev AA
    Antibiot Khimioter; 2008; 53(5-6):28-31. PubMed ID: 19069179
    [No Abstract]   [Full Text] [Related]  

  • 7. How are we creating fluoroquinolone-resistant tuberculosis?
    Bernardo J; Yew WW
    Am J Respir Crit Care Med; 2009 Aug; 180(4):288-9. PubMed ID: 19661251
    [No Abstract]   [Full Text] [Related]  

  • 8. [Respiratory fluoroquinolones and pulmonary tuberculosis treatment when the main drugs are ineffective].
    Lazareva NB; Khaĭmenova TIu; Khaĭmenov AIa
    Antibiot Khimioter; 2008; 53(5-6):14-20. PubMed ID: 19069177
    [No Abstract]   [Full Text] [Related]  

  • 9. Treatment of non-cavitary pulmonary tuberculosis with shortened fluoroquinolone-based regimens: a meta-analysis.
    Alipanah N; Cattamanchi A; Menzies R; Hopewell PC; Chaisson RE; Nahid P
    Int J Tuberc Lung Dis; 2016 Nov; 20(11):1522-1528. PubMed ID: 27776595
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Sparfloxacin in combined therapy for pulmonary tuberculosis].
    Sokolova GB; Khaĭmenova TIu; Lazareva IaV; Khaĭmenov AIa
    Antibiot Khimioter; 2008; 53(5-6):21-7. PubMed ID: 19069178
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment Outcomes with Fluoroquinolone-Containing Regimens for Isoniazid-Resistant Pulmonary Tuberculosis.
    Lee H; Jeong BH; Park HY; Jeon K; Huh HJ; Lee NY; Koh WJ
    Antimicrob Agents Chemother; 2016 Jan; 60(1):471-7. PubMed ID: 26525801
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Effectiveness and Safety of Fluoroquinolone-Containing Regimen as a First-Line Treatment for Drug-Sensitive Pulmonary Tuberculosis: A Systematic Review and Meta-Analysis.
    Lee HW; Lee JK; Kim E; Yim JJ; Lee CH
    PLoS One; 2016; 11(7):e0159827. PubMed ID: 27455053
    [TBL] [Abstract][Full Text] [Related]  

  • 13. First Insight Into the Fluoroquinolone and Aminoglycoside Resistance of Multidrug-Resistant
    Varghese B; Al-Hajoj S
    Am J Trop Med Hyg; 2017 May; 96(5):1066-1070. PubMed ID: 28500800
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Synthesis and tuberculostatic activity of fluoridized 3-Z-hydrazine-2-benzoyl acrylates and their cyclization products].
    Kravcheko MA; Nosova EV; Lipunova GN; Chasovskikh OM; Sokolov VA; Charushin VN
    Probl Tuberk Bolezn Legk; 2003; (7):49-52. PubMed ID: 12939881
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Moxifloxacin plus standard first-line therapy in the treatment of pulmonary tuberculosis: A meta-analysis.
    Chen Z; Liang JQ; Wang JH; Feng SS; Zhang GY
    Tuberculosis (Edinb); 2015 Jul; 95(4):490-6. PubMed ID: 25964137
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [To the optimization and evidence of current chemotherapy regimens for pulmonary tuberculosis].
    Mishin VIu; Chukanov VI; Vasil'eva IA
    Probl Tuberk Bolezn Legk; 2004; (8):7-11. PubMed ID: 15478548
    [No Abstract]   [Full Text] [Related]  

  • 17. [Maxaquin in the combined treatment of tuberculosis].
    Sokolova GB; Mozhokina GN; Kunichan AD; Elistratova NA; Perel'man MI
    Probl Tuberk; 2000; (5):35-9. PubMed ID: 11077850
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fluoroquinolones for the treatment of pulmonary tuberculosis.
    Moadebi S; Harder CK; Fitzgerald MJ; Elwood KR; Marra F
    Drugs; 2007; 67(14):2077-99. PubMed ID: 17883288
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Commentary on: Does empirical treatment of community-acquired pneumonia with fluoroquinolones delay tuberculosis treatment and result in fluoroquinolone resistance in Mycobacterium tuberculosis? Controversies and solutions.
    Hara GL
    Int J Antimicrob Agents; 2012 Mar; 39(3):206-7. PubMed ID: 22305096
    [No Abstract]   [Full Text] [Related]  

  • 20. [Morphologic and biochemical changes in Mycobacterium tuberculosis during chemotherapy].
    Khomenko AG; Fadeeva NI; Golyshevskaia VI
    Probl Tuberk; 1983 Jul; (7):48-54. PubMed ID: 6415652
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.